Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mupirocin
Drug ID BADD_D01504
Description Mupirocin, formerly termed pseudomonic acid A,[A178531] is a novel antibacterial agent with a unique chemical structure and mode of action apart from other antibiotic agents. Produced by fermentation using the organism _Pseudomonas fluorescens_, mupirocin is a naturally-occurring antibiotic that displays a broad-specturm activity against many gram-positive bacteria and certain gram-negative bacteria _in vitro_.[L10580] It primarily works by inhibiting bacterial protein synthesis. Due to its unique mode of action of inhibiting the activity of bacterial isoleucyl-tRNA synthetase, mupirocin does not demonstrate cross-resistance with other classes of antimicrobial agents, giving it a therapeutic advantage.[L10580] It is available in topical formulations only due to extensive systemic metabolism[A178531] and is used in the treatment of impetigo caused by _Staphylococcus aureus_ and _Streptococcus pyogenes_ and traumatic skin lesions due to secondary skin infections caused by _S. aureus_ and _S. pyogenes_. There is also some clinical evidence that suggests the potential role of mupirocin in eradicating nasal carriage of Staphylococci when administered intranasally.[A178531,A178591] Mupirocin is commonly marketed under the brand name Bactroban.
Indications and Usage Indicated for the treatment of impetigo and secondary skin infections, leading to traumatic skin lesions, due to _Staphylococcus aureus_ and _Streptococcus pyogenes_.[L10580]
Marketing Status approved; investigational; vet_approved
ATC Code D06AX09; R01AX06
DrugBank ID DB00410
KEGG ID D01076
MeSH ID D016712
PubChem ID 446596
TTD Drug ID D03JSJ
NDC Product Code 51552-1194; 51927-0010; 68254-2504; 68462-560; 51846-1017; 63187-151; 80425-0254; 81033-020; 21922-029; 68462-180; 70518-1808; 65897-2003; 68254-0010; 0093-1010; 50268-568; 62332-624; 53002-9853; 63187-261; 69238-2029; 76420-128; 45865-722; 63629-9439; 68462-564; 68788-9891; 70166-017; 80425-0246; 62991-2701; 70518-2344; 0904-7284; 0168-0352; 45802-018; 51672-1312; 53002-9850; 63187-015; 63629-8687; 68071-4111; 68788-7993; 38779-2545; 51927-0296; 65897-1003; 49999-644; 53002-9851; 63187-525; 63629-9440; 45802-112; 50090-1587
UNII D0GX863OA5
Synonyms Mupirocin | Pseudomonic Acid A | Mupirocin Calcium | Mupirocin, Sodium Salt | Mupirocin, Lithium Salt | BRL-4910A | BRL 4910A | BRL4910A | Mupirocin, 14C-Labeled | 14C-Labeled Mupirocin | Mupirocin, 14C Labeled | Mupirocin, Calcium Salt (2:1) | Mupirocin, Calcium Salt (2:1), Dihydrate | Pseudomonic Acid | Bactroban
Chemical Information
Molecular Formula C26H44O9
CAS Registry Number 12650-69-0
SMILES CC(C1C(O1)CC2COC(C(C2O)O)CC(=CC(=O)OCCCCCCCCC(=O)O)C)C(C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Skin disorder23.03.03.007--Not Available
Swelling08.01.03.015--Not Available
Tenderness08.01.08.005--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Wound infection12.01.08.012; 11.01.08.010--
Upper respiratory tract congestion22.12.03.033--Not Available
Secretion discharge08.01.03.019--Not Available
Haemorrhage24.07.01.002--Not Available
Application site burn23.03.11.013; 12.07.01.038; 08.02.01.038--Not Available
Sensitisation10.02.01.012; 08.01.05.009--Not Available
The 2th Page    First    Pre   2    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene